Allergan, Inc. (AGN)

Gap down to 48

Upthumb. Kind of pricey. But good growth rate. Excellent balance sheet. Low debt ratio. Good payout. Good cash flow.

Overpriced. P/E 31, P/FCF 66, P/S 3.8, P/TB 22. They are too large to sustain their previous growth, and can't continue to trade at a large premium to similar pharmaceutical and healthcare companies.

good company

Very successful product line with not much comparable competition (Botox, Juvederm). They also developed less expensive and evasive procedures like eye lash treatments. Especially during tough eco times personal (and more affordable) luxuries like the lash and various derma treatments will allow revenue targets being met. AGN will be doing fine b/c of the current economy.

great new cosmetic product approved by fda will increase sales

The potential that Lumigan will explode profits with little in the way of adverse events. A real positive for a Pharma company.

http://www.thestreet.com/story/10451209/1/cramers-mad-money-recap-let-the-deals-begin.html?puc=_htmlbooyah

HEALTH CARE COMPANY

Just a hunch, goes to $80

Terrible P/E ratios but the rest of the fundamentals were good enough to sell me. Medical devices, a complement to pharmaceutical as well as a specialty pharmaceutical niche. Had narrow movement in stock price in the past few weeks and I liked the price being toward its 52 week low. Optimistically, I am looking for strength out of this one in a market that is volatile.

A leader in cosmetic medicine in a US market obsessed with appearance and a growing Baby Boomer population.

I work in ophthalmology, and I see a segment of this company's products. In our industry, most are top-notch. However, looking ahead to uncertain economic times, increased competition and possible regulation, I don't think Botox is going to be as hot a product as it has been. My bet is Allergan will continue to slide.

Allergan has a range of great pharma and device products from opthalmics and dermatology to neurological products. While some may think that lessening use of Botox as a cosmetic due to economics will be a downfall for this company, the potential use for Botox on true medical conditions such as tinnitus, strabismus, and cervical dystonia far outweighs that concern.

It is a growing market and products are well diversified.

looks right for a rebound

potential takeover target.

Good time to buy AFN. As consumer confidence picks up so will cosmetic expenditures pick up.

They reported great earnings and the overall outlook was pretty postive for Allergan.

The focus on the conf call was yesterday was more related to the Botox division and reduction in growth in the NA market due to the economy. But the Botox business is only 10% of the total revenue and they do sell other stuff. Plus Botox is sold everywhere in the world not just in the United States.

I think this is a very good stock and undervalued, it will outperform.